B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Clinical trials for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Immune cells from donors show promise against Hard-to-Treat blood cancers
Disease control OngoingThis early-phase study tests NKX019, a therapy made from donor immune cells (natural killer cells) that are engineered to find and attack cancer cells. It is for adults with certain blood cancers (like lymphoma or leukemia) that have come back or not responded to other treatments…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Nkarta, Inc. • Aim: Disease control
Last updated May 26, 2026 08:42 UTC
-
New combo therapy shows promise for tough blood cancer
Disease control OngoingThis early-phase study tests whether combining two drugs, venetoclax and inotuzumab ozogamicin, is safe and effective for people with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to treatment. About 23 adults with CD22-positive B-ALL will receiv…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated May 26, 2026 08:41 UTC
-
CAR-T therapy offers new hope for kids with stubborn leukemia
Disease control OngoingThis study tests a one-time treatment called tisagenlecleucel (a CAR-T cell therapy) in children and young adults aged 1 to 25 with high-risk B-cell acute lymphoblastic leukemia. Participants have small amounts of cancer remaining after initial chemotherapy. The therapy uses the …
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
Can a second dose of CAR t cells keep leukemia away longer?
Disease control OngoingThis study tests whether giving a second, early infusion of the CAR T-cell therapy tisagenlecleucel can keep the immune system's B cells suppressed longer in children and young adults whose B-cell acute lymphoblastic leukemia has returned or not responded to treatment. The goal i…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 22, 2026 14:01 UTC